MIMEDX GROUP, INC. Q3 FY2026 earnings call

• Strategic Acquisition Progress: MiMedx remains committed to acquiring Senera MedTech, which is accretive and strategically complementary. The FTC issued a second request for information, extending the HSR waiting period, but management views interactions positively and expects an efficient resolution.
• Surgical Business Strength: Despite softer overall procedure volumes industry-wide, surgical volume grew in the mid-teens. Growth was broad-based across placental sheets (AmnioFix, AmnioEffect) and particulate products. A favorable court ruling vacated the FDA’s classification of Axiofil as a biological product, affirming its status as a medical device.
• Patent Litigation Wins: Reached a $25 million settlement with one infringer. Two other major litigation cases are proceeding favorably, with successful defense against patent invalidation attempts by the USPTO.
• Wound Care Market Reset: The business continues to navigate disruptions from 2026 Medicare reimbursement changes, leading to lower pricing and volume in non-center settings. However, wound care center volume grew 7% sequentially and >20% year-over-year, indicating stabilization and patient migration to these sites.
• Operational Efficiency: Right-sized cost structure resulted in positive Adjusted EBITDA ($2 million) and improved gross margin (80%, up 11 percentage points sequentially). Manufacturing throughput and cost reduction initiatives drove these improvements.
• Product Development: Substantial progress on 510(k) submissions for two new surgical products, with at least one clearance expected before year-end. Continued funding of randomized controlled trials for evidence generation.

• Surgical: Net sales of $40 million, representing a 9% year-over-year increase. This segment now accounts for approximately two-thirds (approx. 65%) of total net sales.
• Wound Care: Net sales of $22 million, representing a 71% year-over-year decrease. This segment accounts for the remaining approx. 35% of total net sales.

• Full Year 2026 Net Sales: Updated expectation of $250 million to $260 million.
• Q4 2026 Surgical Growth: Expects high single-digit year-over-year growth.
• Q4 2026 Wound Care Growth: Expects mid-single-digit sequential growth.
• Q4 2026 Gross Margin: Expects margin to approximate Q3 levels (~80%), supported by ongoing cost reductions.
• Q4 2026 SG&A Expense: Expects expense to be 58-60% of net sales.
• Q4 2026 G&A Expense: Expects GAAP G&A to remain consistent with Q3 ($18-$19 million).
• Q4 2026 R&D Expense: Expects expense to remain consistent with Q3 ($3-$3.5 million).

• Regulatory Delays: The FTC's second request for information regarding the Senera acquisition extends the closing timeline and introduces uncertainty, though management remains optimistic.
• Reimbursement Environment: Ongoing disruption from 2026 Medicare reimbursement changes continues to pressure wound care pricing and volumes outside of specialized centers.
• Litigation Costs: Significant legal expenses are incurred for ongoing patent litigation, impacting GAAP net income despite positive Adjusted EBITDA.
• Market Volatility: Unpredictable nature of the wound care market recovery makes precise modeling of volume and price stabilization difficult.

Q: Frank Takkinen asked about the drivers behind higher-than-normal rebate activity in Q3 and how to view rebates going forward. / A: Joe Capper explained that increased rebates were due to short-term promotional activities running through year-end and catch-up adjustments for accounts that unexpectedly hit target thresholds. He noted this was an anomaly for the period rather than a structural change.

Q: Chase Knickerbocker sought visibility on when the wound care business might stabilize and if there are specific inflection points on the calendar. / A: Joe Capper stated that predicting exact stabilization is difficult as the market is only three quarters into the reset. He emphasized that while the final baseline is unclear, MiMedx is well-positioned in wound care centers where their value proposition resonates, suggesting they will likely emerge strongly once the dust settles.

Q: Brad Bowers asked if achieving the 20% combined Adjusted EBITDA margin target depends heavily on the wound care business recovering or if surgical could lead the way alone. / A: Doug Rice indicated that while they prefer wound care to grow, they believe the 20% margin target is achievable within a short timeframe even given current wound care performance, driven by synergies and cost efficiencies from the combined entity.

Q: Frank Takkinen inquired whether the 80% gross margin achieved in Q3 is durable long-term or specific to Q4. / A: Doug Rice attributed the improvement to manufacturing efficiencies and throughput gains from spring cost reductions. He expressed confidence that the margin profile is sustainable, though it may vary slightly based on future product mix.